Cytek Biosciences, Inc. (CTKB) Profit Margins
Over the twelve months to 2026-06-30, Cytek Biosciences, Inc. (CTKB) had gross margin 53.2%, operating margin -21.6%, net margin -39.0%, free cash flow margin -5.8%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTKBCytek Biosciences, Inc.Follow CTKB — free
—
Price chart with a free account
- Market cap
- 726.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Gross margin | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% | 53.2% | |
| Operating margin | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% | -21.6% | |
| Net margin | 2.4% | 1.5% | -6.3% | -3.0% | -33.0% | -39.0% | |
| FCF margin | 0.2% | -13.4% | 0.3% | 10.9% | -4.4% | -5.8% |
USD millions · SEC XBRL
Cytek Biosciences, Inc. — questions
- What is Cytek Biosciences, Inc.'s gross margin?
- 53.2% over the twelve months to 2026-06-30.
- What is Cytek Biosciences, Inc.'s operating margin?
- -21.6% over the twelve months to 2026-06-30.
- What is Cytek Biosciences, Inc.'s net profit margin?
- -39.0% over the twelve months to 2026-06-30.
Every figure on this page comes from Cytek Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.